cd44v6 fitc monoclonal antibody (Thermo Fisher)
Thermo Fisher is a verified supplier 
Thermo Fisher manufactures this product 
86
Structured Review
Thermo Fisher
cd44v6 fitc monoclonal antibody
Cd44v6 Fitc Monoclonal Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd44v6+fitc+monoclonal+antibody/pmc06483002-249-11-16
Average 86 stars, based on 1 article reviews
Cd44v6 Fitc Monoclonal Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd44v6+fitc+monoclonal+antibody/pmc06483002-249-11-16
Average 86 stars, based on 1 article reviews
cd44v6 fitc monoclonal antibody - by Bioz Stars,
2026-10
86/100 stars
Images
1) Product Images from "Cancer stem cell–associated miRNAs serve as prognostic biomarkers in colorectal cancer"
Article Title: Cancer stem cell–associated miRNAs serve as prognostic biomarkers in colorectal cancer
Journal: JCI Insight
doi: 10.1172/jci.insight.125294
Figure Legend Snippet: (A) Schematic representation of CD44 exons. (B) Gene expression of CD44v6 in matched cancer and adjacent normal mucosa tissues in 2 independent cohorts (Mann-Whitney U test). (C) CD44v6 gene expression categorized by tumor stages (cohort 1: n = 184, cohort 2: n = 150, 1-way ANOVA). (D) Kaplan-Meier analysis for overall survival (OS) in 2 independent cohorts (log-rank test). (E) Kaplan-Meier analysis of disease-free survival (DFS) in 2 independent cohorts (log-rank test). (F) Forest plots illustrate the Cox hazard proportional analysis based on overall survival and DFS stratified by CD44v6 expression and clinical factors. *P < 0.05, **P < 0.01, ***P < 0.001.
Techniques Used: Expressing, MANN-WHITNEY
Figure Legend Snippet: (A) Images of sphere-derived cancer stem cells (SDCSCs) and their respective parental cells. (B) Gene expression of pluripotency markers Oct4 and Nanog in SDCSCs and their parental cell lines (n = 3, Mann-Whitney’s U test). (C) Expression of the stemness-suppressive miRNAs miR-34a and miR-200c in SDCSCs and their parental cell lines (n = 3, Mann-Whitney U test). (D) Cytotoxicity from various doses of 5FU (top 2 panels) and oxaliplatin (bottom 2 panels) was assessed for SDCSCs and their respective parental cells lines, HCT116 and HT29. (E) Relative gene expression of CD44 variants in SDCSCs and their parental cell lines (n = 3, Mann-Whitney U test). (F) CD44v6 protein expression in SDCSCs and their parental cell lines, HCT116 and HT29. (G) Immunofluorescence assay of CD44v6 in SDCSCs from HCT116 cells with FITC staining (left) and DAPI nuclear staining (middle); a merged image is shown on the right. *P < 0.05, **P < 0.01, ***P < 0.001.
Techniques Used: Derivative Assay, Expressing, MANN-WHITNEY, Immunofluorescence, Staining
Figure Legend Snippet: (A) CD44v6 protein expression following transient knockdown (KD) in HT29 and HCT116 cell lines. NC, negative control. (B) Cell proliferation of CD44v6 KD cells and parental cell lines (n = 8 per time point, Mann-Whitney U test). (C) Clonogenicity of HCT116 and HT29 cells with and without KD of CD44v6 (n = 6, Mann-Whitney U test). (D) Spheroid formation capacity of HCT116 and HT29 cells with and without KD of CD44v6 (HCT116: n = 20, HT29: n = 8, Mann-Whitney U test). (E) Cytotoxicity of various doses of 5FU (left) and oxaliplatin (right) was assessed for HCT116 cells with and without KD of CD44v6. *P < 0.05, ***P < 0.001.
Techniques Used: Expressing, Negative Control, MANN-WHITNEY
Figure Legend Snippet: (A) FACS analysis of CD44v6-positive and -negative sphere-derived cancer stem cells (SDCSCs) derived from a HCT116 cell line. (B) Spheroid-forming capacity of HCT116- and HT29-derived CD44v6+ and CD44v6– SDCSCs (n = 16, Mann-Whitney U test). (C) Spheroid-forming ability of HCT116 (left) and HT29 (right) CD44v6+ and CD44v6– SDCSCs in the presence of 5FU (top) and oxaliplatin (bottom; n = 6 per time point, Mann-Whitney U test). *P < 0.05, **P < 0.01, ***P < 0.001.
Techniques Used: Derivative Assay, MANN-WHITNEY
Figure Legend Snippet: (A) Heatmap of differentially expressed miRNAs between CD44v6+ and CD44v6– sphere-derived cancer stem cells (SDCSCs). (B) List of upregulated and downregulated miRNAs ranked by P values. (C) List of pathways identified by KEGG analysis based on predicted downstream target genes for differentially expressed miRNAs between CD44v6+ and CD44v6– SDCSCs. Down, downregulated; Up, upregulated.
Techniques Used: Derivative Assay
Figure Legend Snippet: (A) Expression of miR-1246 in CD44v6+ and CD44v6– sphere-derived cancer stem cells (SDCSCs) derived from HCT116 and HT29 cell lines (n = 3, Mann-Whitney U test). (B) Expression of miR-1246 in 5FUR and parental HCT116 cell line (n = 3, Mann-Whitney U test). (C) Correlation analysis between CD44v6 and miR-1246 expression in CRC tissue from clinical cohort 1. (D) miR-1246 expression in cancer tissues versus adjacent normal mucosa (left), and in normal tissue and CRC at different stages (right; 1-way ANOVA). (E) Kaplan-Meier analysis of overall survival and disease-free survival in cohort 2 (log-rank test). *P < 0.05, **P < 0.01, ***P < 0.001.
Techniques Used: Expressing, Derivative Assay, MANN-WHITNEY
Related Articles
Derivative Assay:Article Title: Cancer stem cell–associated miRNAs serve as prognostic biomarkers in colorectal cancer Article Snippet: .. SDCSCs derived from HCT116 and HT26 cell lines were stained with Staining:Article Title: Cancer stem cell–associated miRNAs serve as prognostic biomarkers in colorectal cancer Article Snippet: .. SDCSCs derived from HCT116 and HT26 cell lines were stained with |